Orchid Advocacy
  • Home
    • About Orchid >
      • Why Orchid?
      • ORCHID'S SYSTEMIC FOCUS & "ROOT CAUSE" ANALYSIS APPROACH TO PROBLEM SOLVING WITH A COMMITMENT TO CREATIVITY & INNOVATION
      • Disclaimers, Limitations and An Invitation
      • Orchid Board
      • Orchid Book Club
      • Conjecture, Science & Translational Research & Medicine
      • Orchid Themes & Symbols
      • The Tipping Point
      • Orchid's Website Advertising Policy
      • Statement for Potential Website Contributors
      • Contact
  • Blogs
    • Val's Blog
    • Val's Blog 2
    • ​TRANSLATIONAL/ ​TRANSITIONAL JUSTICE MONDAY
    • NEURO-DIVERSITY Wednesday
    • Olmstead Law & Order Thursday
    • Translational Medicine Friday
    • Translational Love, Relationships & Neuro-Diversity Saturday
  • Orchid's A-Z Index
    • Crisis Services in CO, the US & Around the World
    • Assertive Community Treatment & Flexible ACT Index
    • Housing & Homelessness Index
    • Criminal Justice
    • Innovation Index
    • For More: See the Main Orchid Index Page
  • US Federal
    • THE IMD RULE & ADMIN. ENFORCEMENT OF DISABILITY CIVIL RIGHTS LAWS
    • Medicaid & Supportive Housing & Housing-Related Services
    • CMS' FAILURE TO COVER HOUSING FOR LTC & THE IMD RULE: WHAT THEY HAVE IN COMMON IS DISCRIMINATION
    • National Take
  • Research & Translational Medicine
    • Immunology & Mental Health >
      • Alcoholism & the Immune System & Mental Health
      • Brain Injury, the Immune System & Mental Health
      • Celiac Disease & Sensitivities, the Immune System & Mental Illness
      • Mental Illness & The Immune System
      • Racial Discrimination & the Immune System & Mental Health
      • Trauma & the Immune System & Mental Health
      • ***Physical Health Issues, the Immune System & Mental Health Index
    • University of Chicago: Institute of Translational Medicine
  • Hot Topics
    • What We Want --- SAMHSA Grant Opportunities Due Jan. 22, 2019
    • Anti-Social Personality Disorder >
      • DECONSTRUCTING ANTISOCIAL PERSONALITY DISORDER AND PSYCHOPATHY: A GUIDELINES-BASED APPROACH TO PREJUDICIAL PSYCHIATRIC LABELS [Hofstra Law Review 2013]
      • Personality Disorders -- Unscientific & Vague -- Must Be Reformed
    • Executive Functioning & "Prison Brain" >
      • Job Accommodation Network on Executive Functioning Deficits
    • Medicaid & Medicare Network Adequacy >
      • OIG: STATE STANDARDS FOR ACCESS TO CARE IN MEDICAID MANAGED CARE (Sept. 2014)
      • OIG: ACCESS TO CARE: PROVIDER AVAILABILITY IN MEDICAID MANAGED CARE (Dec. 2014)
      • GAO 15-710: MEDICARE ADVANTAGE: Actions Needed to Enhance CMS Oversight of Provider Network Adequacy (Aug. 2015)
      • CMS: Promoting Access in Medicaid and CHIP Managed Care: A Toolkit for Ensuring Provider Network Adequacy and Service Availability (April 2017)
    • Medicaid Mental Health & Substance Use Disorder Parity >
      • CMS Parity Compliance Toolkit Applying Mental Health and Substance Use Disorder Parity Requirements to Medicaid and Children’s Health Insurance Programs [Jan. 17, 2017]
      • Frequently Asked Questions: Mental Health and Substance Use Disorder Parity Final Rule for Medicaid and CHIP [CMS October 11, 2017]
    • Olmstead Disability Rights >
      • Statement of the Department of Justice on Enforcement of the Integration Mandate of Title II of the Americans with Disabilities Act and Olmstead v. L.C. (2011)
      • Comprehensive Olmstead Planning
      • the Logical Long Term Consequences of our failure to provide Intensive Community MH Treatment
      • Olmstead Nation ---State Pages: How Far to Comply with Olmstead?
  • Take A Walk Around Orchid's Resource Block
  • Colorado Abuse & Neglect Scandals Involving People with Disabilities
  • Mental Health By The Numbers
  • New Science Is Amazing AND It Has HUGE Moral Implications for Our Society: NOW
  • Olmstead & Homelessness
  • Double V
  • " 'Defund the Police" Means 'Invest in the Resources Our Communities Need' " or Don't Cost Shift to the Police
  • VAGUE OLMSTEAD PLANS, EXPENSIVE LITIGATION
  • Updating & Reforming our Understanding & Treatment of "Anti-Social Personality Disorder" Blog
  • Reform of " Anti-Social Personality Disorder" in Criminal Justice
  • CO HB22-1278
  • New Understandings Matter
  • Mental Health, Ethics & Law
  • CO Olmstead Disability Homeless Law & Policy Project
  • Inflammation, the Immune System, Neuro-Developmental Disorders, Psychiatric Disorders, Substance Use Issues & Chronic Disease
  • Microglia and the Brain's Immune System
  • Substance Issues & the Immune System



Translational Medicine Friday

ATP, Parkinson's and the neuro-developmental/Psychiatric continuum

3/15/2024

 
Picture
"The use of oxygen enables a net production of 38 molecules of ATP from one molecule of glucose. Without oxygen, net production is only 2 molecules of ATP.

Because oxygen-requiring reactions (aerobic metabolism) take place only in the mitochondria, it’s clearly advantageous in terms of energy production for cells to contain mitochondria."

Reference:
11.6: Aerobic Metabolism and the Mitochondria - Medicine ...
Picture
Parkinson's Disease in now being viewed as a failure to produce ATP.

  • "ATP is essential in human activities and health. We hypothesize that maintaining ATP levels may help to preserve vulnerable brain cells in neurodegenerative diseases like Parkinson's disease (PD). For this purpose, we developed and tested two types of chemical compounds, one for limiting ATP consumption and the other for enhancing ATP production."
ATP Maintenance via Two Types of ATP Regulators ... - ScienceDirect

Parkinson's is interesting because we think of it as a disorder of mobility, but it also has PSYCHIATRIC SYMPTOMS.
Picture
Psychiatric Symptoms Associated With Parkinson Disease

Many nonmotor aspects of PD, including depression, drug-induced psychosis and impulse control disorders, cognitive impairment, anxiety, and sleep disturbances, are common and are associated with a variety of poor outcomes. 2 These nonmotor symptoms complicate the clinical management of the disorder and are significant determinants of poor quality of life for patients and their caregivers. 3
Are hallucinations a symptom of Parkinson's disease?
  • Hallucinations and delusions are potential complications of Parkinson’s disease (PD). They may be severe enough to be classified as PD psychosis. Hallucinations are perceptions that aren’t really there. Delusions are beliefs that aren’t based in reality. One example is paranoia that persists even when a person is presented with contrary evidence.
Parkinson’s Hallucinations: Delusions and More - Healthline
Currently we estimate the "normal" Brain uses 20% of the oxygen of the body --- the brain uses more oxygen than any other organ of the body.
AUTISM

Autism Spectrum Disorders: The Mitochondria Connection

ourworldandautism.com ›
Why are Autistic People So Tired? Exploring Fatigue in Autism


Sep 21, 2023 · Fatigue in autism can be caused by sleep problems, such as difficulties falling asleep or staying asleep. Additionally, sensory overwhelm, which is common in autism, can lead to
Picture

ADHD

Response variability in Attention-Deficit/Hyperactivity ...

"The immediate effects of deficient ATP production and slow restoration of ionic gradients across membranes of rapidly firing neurons have implications for daily functioning: For individuals with ADHD, performance efficacy would be enhanced if repetitive and lengthy effortful tasks were segmented to reduce concurrent demands for speed and accuracy of response (introduction of breaks into lengthy/effortful activities such as examinations, motorway driving, assembly-line production)."

www.verywellhealth.com › adhd-fatigue-8407263ADHD Fatigue: Understanding the Connection - Verywell Health
Jan 4, 2024 · Fatigue is a common symptom in those with ADHD. Fatigue often brings tiredness and stress and can lead to burnout. Though the exact cause can be unknown and vary from person
Picture
MOOD DISORDERS

More recent studies showed that a decrease in the astrocytic release of ATP in the prefrontal cortex and hippocampus is a major cause of mood disorders. It is an attractive hypothesis that compensatory increases in P2X7Rs in these areas of the brain are the immediate actuators of MD and BD.
www.frontiersin.org › articles › 10Frontiers | Pathological ATPergic Signaling in Major ...

www.ncbi.nlm.nih.gov › pmc › articles
The relationship between fatigue and psychiatric disorders ...
(2009)


Fatigue and psychiatric disorders frequently occur comorbidly and share similar phenomenological features. There has been debate as to whether chronic fatigue, or neurasthenia, should be
Picture
SCHIZOPHRENIA

www.ncbi.nlm.nih.gov › pmc › articles
Schizophrenia as metabolic disease. What are the causes?

Jan 19, 2023 · Purigenic signaling as a mechanism is Schizophrenia. ATP and adenosine work as neurotransmitters. ATP plays the role of the excitatory transmitter, while adenosine plays the


trialsjournal.biomedcentral.com › articles › 10Assessment of the efficacy of a fatigue management therapy in ...
Sep 17, 2020 · First, lack of energy, one of the main characteristics of fatigue, is frequently encountered in individuals with schizophrenia. Second, fatigue is a common and severe symptom

The Neuro-Developmental - Psychiatric Continuum and "Successful aging"

2/16/2024

 
Picture
Bodies of People With Mental Illness Are Biologically Older Than Their Actual Age
Picture
Neuroinflammation and Oxidative Stress in the Pathogenesis of Autism Spectrum Disorder (2023)
1 Department of Neuroscience and Cell Biology, Graduate School of Medicine, Osaka University, Japan
2 United Graduate School of Child Development, Osaka University, Japan
3 Global Center for Medical Engineering and Informatics, Osaka University, Japan
4 Addiction Research Unit, Osaka Psychiatric Research Center, Osaka Psychiatric Medical Center, Osaka, Japan
5 SANKEN (Institute of Scientific and Industrial Research), Osaka University, Japan
In this review, we discuss the inflammation and oxidative stress in the pathophysiology of ASD, particularly focusing on maternal immune activation (MIA).

MIA is a one of the common environmental risk factors for the onset of ASD during pregnancy.

It induces an immune reaction in the pregnant mother’s body, resulting in further inflammation and oxidative stress in the placenta and fetal brain.

These negative factors cause neurodevelopmental impairments in the developing fetal brain and subsequently cause behavioral symptoms in the offspring.
3 Big Takeaways from the Research
Picture
Neuroscience News

Protein Key to Neuroprotection and Aging Discovered (Dec. 2023)

The study emphasizes the potential of this discovery for developing new therapies for age-related diseases and promoting successful nervous system aging.

Source: LSU

Scientists at LSU Health New Orleans’ Neuroscience Center of Excellence, led by Nicolas Bazan, MD, PhD, Boyd Professor and Director, have identified a new mechanism that regulates a protein key for cell survival.

It appears to protect against the excessive oxidative stress that precedes the development of neurodegenerative diseases of the brain and eye.

Results are published in the Nature journal, Cell Death & Disease.
Picture
Elovanoid-N34 modulates TXNRD1 key in protection against oxidative stress-related diseases (2023)
Picture
Lipid mediators in the regulation of innate and adaptive immunity (2023)
Picture
Emerging roles of innate and adaptive immunity in Alzheimer’s Disease (2022)
Picture
Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention (2020)

More Hard Issues:  Homicidality, SUICIDALITY and the Imperfect world of psychiatric medications

1/24/2024

 
Val's Take
  • Sometimes we think serious, potentially catastrophic mental illness is not in the middle and upper middle class suburbs --- but it is.
  • That was seemingly proven once again by the killing of a father by his thirty-something son with "schizophrenia" in Highlands Ranch.
  • One of the ideas that the parents seemingly had and that clinicians have historically had and even advocates had in the beginnings of the MENTAL HEALTH MOVEMENT ----- "JUST TAKE THE DAMN MEDICATION."
  • So if people find the medication helpful --- they generally are taking it, and they are generally lobbying to ensure access to the medication at a reasonable price.
  • One of the places you see this is for people where the GENERIC is NOT going to be an ADEQUATE SUBSTITUTE.
  • In some ways, the current Activist Mental Health Movement is made up of a significant percentage of people in which the medication didn't work that well or made things worse.
  • In addition to that, sometimes Executive Functioning may be so impaired that adhering to a medication regime is not realistic.
  • While I think it was idiosyncratic mental health patients that have pushed this issue, Clinicians are more and more sophisticated about this issue as well --- and will do genetic testing if it is available for that particular medication and are on the lookout for side effects that would indicate the discontinuation of that particular medication.
TedTalk --- David Anderson of Cal-Tech
Most Psychiatric Medications work on the Brain -- Globally --- NOT SPECIFIC NEURAL CIRCUITS -- that can do more harm than good.
Picture
Pharmacogenetic Information & News
How Does Genetic Testing for Psychiatric Medication Work? (2017)
BUT what if --- you don't have a current medication or treatment that will bring the person into a RANGE in which the person can function without being a danger to others, themselves or "gravely disabled"?
TWO THINGS:
  • We need some place safe for that person to live
    • For some people that is a Secure Placement.
    • It is not for most people
  • Even if it is a Secure Placement, it needs to be comfortable and the person needs to have the ability to work with Clinicians and Peers to develop their "STRENGTHS" which often are IDIOSYNCRATIC -- and accommodations and workarounds for Executive Functioning Issues.
Not acknowledging the complexity of psychiatric medication in 2024 and failure to provide "contingency planning" if the medication:
  • Doesn't work for the person or well enough
  • Makes things worse
  • The person can't manage the administration
  • It's not clear what treatment would work
  • Etc.

IS MAKING US LESS SAFE.

Neuro-Diversity, Metabolism, Diet and the Need for Precision Medicine

1/20/2024

 
So to me the important thing about "Maternal Immune Activation" is "DYSREGULATION" of MULTIPLE SYSTEMS OF THE BODY.

And one of the BIG KEYS to that is "MITOCHONDRIA."
Down Syndrome based on research from the University of Colorado School of Medicine is now being conceptualized as an IMMUNE DISORDER.  See also Mayo Clinic on general Down Syndrome information.

Nobody is expecting Down Syndrome to be REVERSED by "DIET" alone.

High IQ Developmental Difference/Disorder --- the reality of that is not something we're really willing to accept.   I'm not saying we should "ACCEPT IT and DO NOTHING" ---
  • But there can be much more of looking for a "QUICK FIX" --- that may in fact help --- may even be LIFE SAVING
  • Even as the Developmental Aspects are shrugged off, ignored or never appreciated in the first place.
Picture
October 25, 2023

Metabolomic Biomarker Signatures for Bipolar and Unipolar Depression
Picture
Maternal Inflammation During Pregnancy and Offspring Brain Development:

The Role of Mitochondria


"The association between maternal immune activation (MIA) during pregnancy and risk for offspring neuropsychiatric disorders has been increasingly recognized over the past several years. "

Picture
Critical role of dysfunctional mitochondria and defective mitophagy in autism spectrum disorders (2021)

 Affiliations
  •     Hengyang Key Laboratory of Neurodegeneration and Cognitive Impairment & Institute of Neuroscience, Hengyang Medical College, University of South China, Hengyang, Hunan, 421001, People's Republic of China; Lhasa Guangsheng Hospital, Lhasa, People's Republic of China.
Picture

Translational Neuroscience: 
Toward New Therapies
​
Chapter 3
Psychotic Disorders and the Neurodevelopmental Continuum

Michael J. Owen
Picture
"EMBO" stands for Excellence in the Life Sciences in Europe and Around the World
Metabolic Mind:  Interview with Dr. Chris Palmer at Harvard.
One of the current big ideas in PSYCHIATRIC DISORDERS is around METABOLISM and a KETOGENIC DIET.

This is being promoted by a number of academics and organizations including METABOLIC MIND.


Above is an interview with Dr. Chris Palmer at Harvard.  I find SOME of Dr. Palmer's ideas very interesting --- I am concerned that there is not an appreciation of some of the DEVELOPMENTAL ASPECTS of this.
Mental Illness & Metabolism
What are the basic rules for keto?

Keto basics


"The ketogenic diet is a very low carb, high fat diet that shares many similarities with the Atkins and low carb diets.

"It involves drastically reducing carbohydrate intake and replacing it with fat. This reduction in carbs puts your body into a metabolic state called ketosis.
"When this happens, your body becomes incredibly efficient at burning fat for energy. It also turns fat into ketones in the liver, which can supply energy for the brain (6Trusted Source).

"Ketogenic diets can cause significant reductions in blood sugar and insulin levels. This, along with the increased ketones, has some health benefits."
See Also:
The Endocrine System
How does the Microbiome Connect to the Brain, the Endocrine System & the Immune System
Physical Health Issues, the Immune System & Mental Health
Picture
Systematic review of mitochondrial genetic variation in attention-deficit/hyperactivity disorder (2022)


"These studies all reported on mitochondrial genetic variation in ADHD cases such as increased copy number, single-nucleotide polymorphisms, and haplogroup associations.

"This initial review of the experimental literature suggests mitochondrial genetic variation, in both the mitochondrial DNA and nuclear-encoded mitochondrial genes, may indeed contribute to ADHD pathophysiology.

"The studies reviewed here provide promising evidence for future research to further examine the mitochondrial genetics contributing to ADHD pathophysiology.

"We suggest that expansion of investigations into mitochondrial mechanisms may have potential to inform new treatment options for ADHD."

Immune synaptopathies: how maternal immune activation impacts synaptic function during development (2023)

A DSM 5 Classification System that Isn't Good Enough

1/16/2024

 
Our current classification system contained in the DSM 5 is not supported by the research.
  • What is supported by the research is something much more DEVELOPMENTAL in which diagnostic categories are not fixed..
  • That has clinical, legal and policy ramifications.

Neurodevelopmental disorders (NDD) without boundaries: research and interventions beyond classifications (2023)

Picture
"Both genetic and environmental factors, along with clinical and imaging features, argue toward a continnum between NDD (Neuro-Developmental Disorders) but also with adult psychiatric presentations.

"This new paradigm could modify the therapeutic strategy, with the development of large-spectrum treatments or new psychotherapies addressing co-occuring symptoms."
Picture
December 12, 2023

The Ups and Downs of Bipolar Disorder

National Institute of Mental Health feature story on Josh Santana who was academically gifted, had ADHD and Bipolar Disorder.
King's College London
Thinking Twice About ADHD and Autism Spectrum Disorder (2019)
Picture
Autism and Beyond: Unveiling Overlapping Neurotypes

January 24, 2024

Key Facts:

  1. The study found a substantial overlap in neurodivergence, with 76.2% of autistic children displaying traits of other neurotypes, including ADHD.
  2. Over 55% of children assessed for autism might also meet the diagnostic threshold for ADHD, highlighting the necessity of holistic neurotype assessments.
  3. Despite the clinical overlap, only 26% of children with additional traits were investigated for an underlying diagnosis, stressing the need for more comprehensive evaluation methods.
Source: University of Glasgow
Affiliations
  • 1 GHU-Paris Psychiatrie et Neurosciences, Paris, France.
  • 2 Excellence Centre for Autism and Neuro-Developmental Disorders, Child and Adolescent Psychiatry Department, Robert Debré Hospital, Paris Cité University, Paris, France.
  • 3 Immunology, Immunopathology, Immunotherapy, INSERM U959, Sorbonne University, Paris, France.
  • 4 Université de Paris, INSERM U1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France.
  • 5 Child and Adolescent Psychiatry Department, Saint-Etienne University Hospital and CNRS UMR 5229, Institute of Cognitive Neuroscience Marc Jeannerod, University Lyon 1, Bron, France.
  • 6 Child Mind Institute, New York, USA.
  • 7 Univ. Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France.
  • 8 CHU Montpellier-Saint Eloi Hospital, University of Montpellier, Unit of Child and Adolescent Psychiatry (MPEA1), Montpellier, France.
  • 9 Center for Research in Epidemiology and Population Health (CESP), INSERM U 1018, Paris-Saclay University, Villejuif, France.
  • 10 Department of Pediatrics, Sainte Justine Hospital Research Center, University of Montreal, Montreal, QC, H4A3J1, Canada.
  • 11 INSERM-UMR1163, Université Paris Cité, Institut Imagine, Paris, France.
  • 12 Faculty of Medicine, University of Tours, Tours, France.
  • 13 Autism and NDD GIS (GIS Autisme et Troubles du Neurodéveloppement), Paris, France.
  • 14 Autism and NDD GIS (GIS Autisme et Troubles du Neurodéveloppement), Paris, France. [email protected].
  • 15 Department of Psychiatry, McGill University, Montreal, Canada.
Science Up
Shared Genes & Psychiatric Disorders

Mirror Neurons innately tuned to aggression

1/5/2024

 
med.stanford.edu ›

mirror-neurons-aggression


Scientists discover mirror neurons in mice and find they’re ...


Feb 15, 2023 · The researchers found also that these mirror neurons seemed innately tuned to aggression, even in mice that had never witnessed or engaged in aggressive behavior. They did
BUT . . .
Picture

Unlocking Anger’s Potential:

A Surprising Key to Goal Achievement


Alice Merton -- No Roots
"A thousand times I've seen this road.  A thousand times."

Dec. 5, 2023
Cerebellar Glia Influence Aggression Level

Mirror Neurons & Aggression


Does a Mirror-Trap reactivate aggression-mirroring neurons?
  • We used a genetically encoded mirror-TRAP strategy to functionally interrogate these aggression-mirroring neurons. We find that their activity is essential for fighting and that forced activation of these cells triggers aggressive displays by mice, even toward their mirror image.
Hypothalamic neurons that mirror aggression - PubMed
Picture

Cortical Thickness & the Neurobiology of 6 Psychiatric

12/10/2023

 
Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders (2021)

JAMA (Journal of the American Medical Assn.) Psychiatry


Conclusions and relevance:   In this study, shared neurobiologic processes were associated with differences in cortical thickness across multiple psychiatric disorders. These processes implicate a common role of prenatal development and postnatal functioning of the cerebral cortex in these disorders.

[See Cleveland Clinic:  Cerebral Cortex]


Affiliations
  • 1 Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • 2 Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada.
  • 3 The Hospital for Sick Children, Toronto, Ontario, Canada.
  • 4 Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • 5 Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles.
  • 6 Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Australia.
  • 7 Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • 8 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • 9 Department of Psychiatry, Yale University, New Haven, Connecticut.
  • 10 Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
  • 11 University of Groningen, University Medical Center Groningen, Department of Biomedical Sciences of Cells and Systems, Cognitive Neuroscience Center, Groningen, the Netherlands.
  • 12 Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Spain.
  • 13 FIDMAG Germanes Hospitalàries Research Foundation, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Catalonia, Spain.
  • 14 The Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute, University of Toronto, Toronto, Ontario, Canada.
  • 15 Department of Pediatrics University of Toronto, Ontario, Canada.
  • 16 Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, Scotland.
  • 17 Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM.
  • 18 The Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • 19 Social, Genetic and Developmental Psychiatry Centre; Institute of Psychiatry, Psychology and Neuroscience; King's College London, London, England.
  • 20 Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.
  • 21 INT UMR 7289, Aix-Marseille Université, CNRS, Aix-en-Provence, France.
  • 22 Department of Psychiatry, Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria; Centro de Investigación Biomédica en Red de Salud Mental, Santander, Spain.
  • 23 Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, Maastricht University, the Netherlands.
  • 24 Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany.
  • 25 Department of Genetics, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
  • 26 The Research Institute of Pediatrics and Child Health of the Central Clinical Hospital of the Russian Academy of Sciences of the Ministry of Science and Higher Education of the Russian Federation, Moscow, Russia.
  • 27 Magnetic Resonance Image Core Facility, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • 28 University of Münster, Department of Psychiatry, Münster, Germany.
  • 29 Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Australia.
  • 30 Psychiatry and Clinical Psychobiology, Division of Neuroscience, Scientific Institute Ospedale San Raffaele, Milano, Italy.
  • 31 Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
  • 32 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Psychiatry, Department of Anatomy & Neuroscience, Amsterdam Neuroscience, Amsterdam, the Netherlands.
  • 33 Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Department of Psychiatry, Utrecht, the Netherlands.
  • 34 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona Bipolar Disorders and Depressive Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.
  • 35 Department of Psychiatry, University of Basel, Basel, Switzerland.
  • 36 McLean Hospital, Harvard Medical School, Belmont, Massachusetts.
  • 37 School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.
  • 38 Institute for Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany.
  • 39 Laboratory of Psychiatric Neuroimaging (LIM-21), Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • 40 Department of Developmental Neuroscience - IRCCS Fondazione Stella Maris, Pisa, Italy.
  • 41 Department of Clinical and Experimental Medicine, University of Pisa.
  • 42 Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, Georgia.
  • 43 Department of Child and Adolescent Psychiatry and Psychology, Hospital Clinic, Barcelona, Spain.
  • 44 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM); University of Barcelona, Spain.
  • 45 Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway, H91 TK33 Galway, Ireland.
  • 46 School of Psychiatry, University of New South Wales, Randwick, New South Wales, Australia.
  • 47 Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • 48 Department of Neuroscience, Brighton and Sussex Medical School, University of Sussex, Brighton, England.
  • 49 Centre for Integrative Neuroscience and Neurodynamics, School of Psychology and Clinical Language Sciences, University of Reading, Reading, England.
  • 50 Departments of Paediatrics and Psychiatry, University of Melbourne, Melbourne, Australia.
  • 51 Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Tübingen, Tübingen, Germany.
  • 52 Department of Psychiatry, Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Santander, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Departamento de Psiquiatria, Universidad de Sevilla, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.
  • 53 Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London UK; Zurich Center for Neuroeconomics, University of Zurich, Zurich, Switzerland.
  • 54 Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, Minnesota.
  • 55 Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, Sackler Institute for Translational Neurodevelopment, London, London, England.
  • 56 Orygen, Melbourne, Australia.
  • 57 Department of Psychiatry, Amsterdam UMC, Amsterdam, the Netherlands.
  • 58 IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • 59 Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
  • 60 Department of Psychology, School of Arts and Social Sciences, City, University of London, Northampton Square, Clerkenwell, London, England.
  • 61 Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, TU Dresden, Dresden, Germany.
  • 62 Department of Psychiatry and Biological Sciences, Albert Einstein College of Medicine, the Bronx, New York.
  • 63 University Medical Center Goettingen, Department of Psychiatry and Psychotherapy, Systems Neuroscience and Imaging in Psychiatry, Göettingen, Germany.
  • 64 Department of Psychiatry, University of Tuebingen, Tuebingen, Germany.
  • 65 Behavioral Neuroscience Department, Oregon Health & Science University, Portland.
  • 66 Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York.
  • 67 Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • 68 Child OCD and Anxiety Disorders Program, Department of Psychiatry, University of Michigan Medical School, Ann Arbor.
  • 69 San Francisco VA Medical Center, San Francisco, California.
  • 70 Department of Psychiatry, Trinity College Dublin, Dublin, Ireland.
  • 71 University of East London, School of Psychology, London, England.
  • 72 Neuroscience Research Australia (NeuRA), Sydney, New South Wales, Australia.
  • 73 Department of Neuroscience, Brighton and Sussex Medical School, Brighton, England.
  • 74 Tommy Fuss Center for Neuropsychiatric Disease Research, Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • 75 Central Clinical Hospital of the Russian Academy Sciences, Moscow, Russia.
  • 76 Department of Psychology, Stanford University, Stanford, California.
  • 77 Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.
  • 78 Department of Psychiatry, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
  • 79 Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
  • 80 Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital, Heidelberg, Germany.
  • 81 FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain.
  • 82 Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • 83 Department of Bioengineering, Imperial College London, London, England.
  • 84 Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • 85 Department of Biomedicine, University of Bergen, Bergen, Norway.
  • 86 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia.
  • 87 University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion regulation (ICPE), Groningen, the Netherlands.
  • 88 Department of Experimental Psychology, Vrije Universiteit, Amsterdam, Netherlands.
  • 89 Genentech Inc, South San Francisco, California.
  • 90 Department of Psychology, University of Oslo, Oslo, Norway.
  • 91 Research Center for Child Mental Development, Chiba University, Chiba, Japan.
  • 92 Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco.
  • 93 University of Groningen, University Medical Center Groningen, Department of Child and Adolescent Psychiatry, Groningen, the Netherlands.
  • 94 Radboud University Medical Center, Karakter University Center of Child And Adolescent Psychiatry, Nijmegen, the Netherlands.
  • 95 Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland.
  • 96 National Institute of Mental Health, Klecany, Czech Republic.
  • 97 Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • 98 Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
  • 99 Department of Psychiatry and Psychotherapy, Philipps University Marburg, Marburg, Germany.
  • 100 University of Oxford, Oxford, England.




  • 101 Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
  • 102 Department of Internal Medicine, First Affiliated Hospital of Kunming Medical University, Kunming. China.
  • 103 Research Institute of Pediatrics and child health of the Central clinical hospital of the Ministry of Science and Education, Moscow, Russia.
  • 104 Department of Psychiatry, Philipps-University Marburg, Marburg, Germany.
  • 105 Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
  • 106 Department of Neuroradiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
  • 107 Child Neuropsychology Section, Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital RWTH Aachen, Aachen, Germany.
  • 108 Child Neuropsychology Section, University Hospital RWTH Aachen, German; JARA-Brain Institute II Molecular Neuroscience and Neuroimaging, Research Centre Juelich, Juelich, Germany.
  • 109 Department of Psychiatry and Psychotherapy, University of Bonn, Germany.
  • 110 Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea.
  • 111 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • 112 Mental Health Research Center, Moscow, Russia.
  • 113 Division of Molecular Psychiatry, Center of Mental Health, University of Würzburg, Würzburg, Germany.
  • 114 SA MRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry, Stellenbosch University, Stellenbosch, South Africa.
  • 115 Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil.
  • 116 Department of Biological and Medical psychology, University of Bergen, Bergen, Norway.
  • 117 Departments of Psychiatry and Pediatrics, University of Calgary, Calgary, Alberta, Canada.
  • 118 University Centre for Information Technology, University of Oslo, Oslo, Norway.
  • 119 Developmental Imaging, Murdoch Children's Research Institute, Melbourne, Australia.
  • 120 Group of Research in Mental Health, Institut d'Investigació Biomèdica Sant Pau, IIBSant Pau; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
  • 121 Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
  • 122 Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • 123 Department of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
  • 124 McMaster University, Mood Disorders Program, SJH Hamilton, Hamilton, Ontario, Canada.
  • 125 Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
  • 126 Department of Forensic and Neurodevelopmental Science, King's College London, London, England.
  • 127 Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry Psychology and Neuroscience, King's College, London, England.
  • 128 Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston.
  • 129 OCD clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
  • 130 Department of Pediatrics, University of California, Irvine.
  • 131 Center for MR Research, University Children's Hospital, Zürich, Switzerland.
  • 132 Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
  • 133 Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Emma Neuroscience Group, department of Pediatrics, Amsterdam Reproduction and Development, Amsterdam, the Netherlands.
  • 134 Center for Neurobehavioral Genetics, University of California Los Angeles.
  • 135 Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • 136 Neuroimaging Unit, Technological Facilities, Valdecilla Biomedical Research Institute IDIVAL; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Santander, Spain.
  • 137 Neuroscience Research Australia, Sydney, Australia.
  • 138 Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, England.
  • 139 Melbourne Neuropsychiatry Centre, University of Melbourne, Melbourne, Australia.
  • 140 Department of Psychology (Biological Psychology, Clinical Psychology, and Psychotherapy), and Center of Mental Health, University of Würzburg, Würzburg, Germany.
  • 141 Division of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland; Child and Adolescent Mental Health Center, Mental Health Services, Capital Region of Denmark, Denmark.
  • 142 Department of Psychiatry and Human Behavior, University of California, Irvine.
  • 143 Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain; Group of Psychiatry, Mental Health and Addictions, Vall d'Hebron Research Institute, Barcelona, Catalonia, Spain; Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
  • 144 Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Catalonia, Spain.
  • 145 Priority Centre for Brain & Mental Health Research, The University of Newcastle, Callaghan, New South Wales, Australia.
  • 146 Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany.
  • 147 Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
  • 148 National Institute for Nuclear Physics, Pisa Division, Pisa, Italy.
  • 149 Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.

  • 150 Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • 151 Center for Depression, Anxiety, and Stress Research, McLean Hospital, Harvard Medical School, Belmont, Massachusetts.
  • 152 Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, Facultad de Psicologia, Universidad Autónoma de Madrid.
  • 153 Neuroscience Research Australia, Sydney, New South Wales, Australia.
  • 154 Department of Child and Adolescent Psychiatry, RWTH Aachen University Hospital, Aachen, Germany.
  • 155 National Human Genome Research Institute and National Institute of Mental Health, Bethesda, Maryland.
  • 156 School of Psychology, Deakin University, Geelong, Melbourne, Australia.
  • 157 West Region, Institute of Mental Health, Singapore.
  • 158 Columbia University Irving Medical Center, New York, New York.
  • 159 Center for Child and Adolescent Mental Health, Institute of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway.
  • 160 Pediatric OCD Consultation Clinic, Anxiety Treatment and Research Center, SJH Hamilton, Ontario, Canada.
  • 161 Department of Psychiatry, New York University School of Medicine, Nathan Kline Institute, New York.
  • 162 Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
  • 163 Anxiety Disorders Center, The Institute of Living, Hartford, Connecticut.
  • 164 Laboratory of Medical Physics and Magnetic Resonance - IRCCS Fondazione Stella Maris, Pisa, Italy.
  • 165 Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, the Netherlands.
  • 166 Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands.
  • 167 Department of Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • 168 Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Amsterdam, the Netherlands.
  • 169 Academic Child Psychiatry Unit, Department of Pediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Australia.

  • 170 Hospital Clinic, University of Barcelona, Spain.
  • 171 Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona, Cerdanyola del Vallès, Barcelona, Spain.
  • 172 Instituto ITACA, Universitat Politècnica de València, Valencia, Spain.
  • 173 Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
  • 174 Department for Child and Adolescent Psychiatry, University Hospital RWTH Aachen, Aachen, Germany.
  • 175 Department of Psychology, University of Bath, Bath, England.
  • 176 Clinical Translational Neuroscience Laboratory, University of California Irvine, Irvine, CA; Center for the Neurobiology of Learning and Memory, University of California, Irvine.
  • 177 German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Germany.
  • 178 University of California San Francisco, Department of Psychiatry, Division of Child and Adolescent Psychiatry, University of California, San Francisco, Weill Institute for Neurosciences.
  • 179 Department of Child and Adolescent Psychiatry, New York University Child Study Center, Hassenfeld Children's Hospital at NYU Langone, New York.


  • 180 Seoul National University Hospital, Seoul, Republic of Korea.
  • 181 Department of Psychiatry, First Affiliated Hospital of Kunming Medical University, Kunming, China.
  • 182 Departments of Human Genetics and Psychiatry, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
  • 183 Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
  • 184 Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud UMC, Nijmegen, the Netherlands.
  • 185 Donders Centre for Cognitive Neuroimaging, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • 186 Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • 187 Department of Psychiatry, Amsterdam UMC, location VUMC, Amsterdam, the Netherlands.
  • 188 Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia.
  • 189 SAMRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
  • 190 Psychology Department and Neuroscience Institute, Georgia State University, Atlanta, Georgia.
  • 191 Departments of Psychology and Psychiatry, University of Toronto, Toronto, Ontario, Canada.

Significant correlation between Altitude and Suicide Mortality among US Veterans

12/9/2023

 
Conjecture

Colorado Medicaid Providers might want to partner in a more STRUCTURED & SYSTEMIC Way to address issues of ALTITUDE and Mental Health with---
  • National Jewish Hospital in Denver
    • They are a national leader in respiratory work & have a SLEEP LAB.
  • My take has been if the COPING MECHANISM you need is OXYGEN ---- THERE REALLY is no SUBSTITUTE.
  • People should be screened for:
    • Deviated Septum
    • Allergies
    • Asthma
    • Sleep Apnea  --- sleep apnea can be due to a lot of things ---
      • Obstructive sleep apnea
      • Substance-Induced sleep apnea, and
      • Altitude induce sleep apnea
        • Sleep apnea has been associated with bipolar disorder according to Taiwan University.
    • Etc.
I re-iterate I don't think the ONLY issue in Mental Health is ALTITUDE, SLEEP APNEA, etc. --- but I think this is an issue that helps explain why Mountainous Regions have significantly above Average Suicide Rates.If we want to say there are other SOCIAL FACTORS --- that's fine --
  • BUT STOP IGNORING ALTITUDE and other Complicated Factors to getting OXYGEN to the BRAIN.
  •  There should be a SYSTEM OF COORDINATED CARE to have people evaluated for oxygen issues and screened for mental health issues. 
I think people can sometimes feel EMBARRASSED by these really MUNDANE ISSUES that could potentially lead to something more SERIOUS or Bizarre Behavior that's even MORE EMBARRASSING or WORSE.
High Altitude & Sky High Suicide Rates
The Need for a New Integrated DSM
Picture
An examination of the association between altitude and suicide deaths, suicide attempts, and suicidal ideation among veterans at both the patient and geospatial level (Sept. 2022)
Highlights

•There is a significant correlation between altitude and suicide mortality rate for U.S. veterans.

•The association between altitude and suicide deaths is higher than the association with suicide attempts or ideation.

•Controlling for relevant factors improves the correlation.
Our work suggested that geospatial factors such as altitude may be significant and should be included in suicide prediction models.

Future studies should incorporate altitude and other hypoxia-related variables into the suicide prediction models in order to further investigate how altitude and associated variables are related to suicide.
Affiliations
  • 1 Applied Mathematics and Computational Research Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
  • 2 Applied Mathematics and Computational Research Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
  • 3 Departments of Mathematics and Statistics, University of California, Los Angeles, CA, USA.
  • 4 Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, USA.
  • 5 Departments of Computer Science, Hood College, Frederick, MD, USA.
  • 6 VISN 4 Mental Illness Research, Education, and Clinical Center, Center of Excellence, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, PA, USA.
  • 7 Durham Veterans Affairs (VA) Health Care System, Durham, NC, USA; VA Mid-Atlantic Mental Illness Research, Education and Clinical Center, Durham, NC, USA; Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.
  • 8 Durham Veterans Affairs (VA) Health Care System, Durham, NC, USA; VA Mid-Atlantic Mental Illness Research, Education and Clinical Center, Durham, NC, USA; Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA; VA Health Services Research and Development Center of Innovation to Accelerate Discovery and Practice Transformation, Durham, NC, USA.
  • 9 Million Veteran Program, Department of Veterans Affairs, USA.

NO Competent Health Care System If We Don't Understand Developmental Neuro-Inflammation

10/20/2023

 
& We Certainly Won't Have a Competent Mental Health System If We Don't Understand Developmental Neuro-Inflammation ---
We are spending an ENORMOUS amount of money on HEALTHCARE in this Society.
  • One of the go to BROMIDES is --- WE NEED MORE PERSONAL RESPONSIBILITY
  • We have often thought that our CHRONIC DISEASE EPIDEMIC is a result in large part of people NOT TAKING PERSONAL RESPONSIBILITY.
 
  • At the same time we're coming to terms with:
    • The CONTRADICTIONS inherent in BOTH SIDES of the PRO LIFE DEBATE, and
    • The DEVELOPMENTAL ORIGINS of many BEHAVIOR ISSUES.
      • Those DEVELOPMENTAL ORIGINS are often SEX SPECIFIC and can be more obvious in males;
      • BUT the DEVELOPMENTAL ORIGINS often involve MATERNAL IMMUNE ACTIVATION (MIA)
 
  • There are probably a lot of proteins of 20,000 that are disrupted by Maternal Immune Activation ---
    • C-Reactive Protein is a protein that keeps coming up with regard to Neuro-Developmental & Psychiatric Disorders
    • Mayo Clinic --- C-Reactive Protein Test as relates to Heart Disease
Picture
Should you be tested for inflammation? (Mar. 2022)
Picture
C-reactive protein as a potential biomarker in psychiatric practice: Are we there yet? (2021)
Results: The accumulating evidence from large studies and meta-analyses allows us to understand the role of CRP in major psychiatric disorders and increase our understanding of specific symptoms and subtypes of disorders.

CRP may be considered a 'psychiatric biomarker' which can alert clinicians about neuroinflammation, adverse effects of medications, cardiometabolic status, co-morbidities, and may also predict clinical outcomes and guide optimal treatment selection.
CAVEAT:  The Study is NOT saying all questions have been answered but given "ACCUMULATING EVIDENCE" C-Reactive Protein may be considered a "BIO-MARKER."
Picture
Potential Inflammatory Biomarker in Patients with Attention Deficit Hyperactivity Disorder (Nov. 2022)
Picture
Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. (2018)
Picture
C-Reactive Protein during pregnancy is associated with different brain morphology, Autism, considered  a potential biomarker for psychiatric illness, a potential biomarker for ADHD, is associated with Schizophrenia, Bipolar Disorder and Depression.
Based on what CRP itself is, there is an obvious link between this protein and inflammation. Because of this, high CRP levels are a concern as well, primarily because they can be an indicator of chronic inflammation. This is true especially if high CRP levels remain for long periods of time without receding.

Chronic inflammation can be incredibly harmful to the body. Why is this? Inflammation signals white blood cells to release “free radicals” into the body and kill harmful stimuli.

The problem with this is that the free radicals damage the surrounding areas of where a harmful stimuli might be, harming and even killing our cells. This process, when prolonged, greatly increases the risk for cancer cells to develop.

This type of research has discovered that chronic inflammation plays a role in the development of many different diseases and health conditions. Some of these include arthritis, diabetes, heart disease, lupus, neurodegeneration like Alzheimer’s, and even Parkinson’s disease. Recent research indicates it might even be linked to depression.

Unfortunately, there is still much more research to be done in regards to actually treating and preventing chronic inflammation, and in turn keeping CRP levels low. As it stands, Johns Hopkins Medicine states that treating chronic ailments, like high CRP levels,is a challenge.
Picture
Elevated Maternal C-Reactive Protein and Autism in a National Birth Cohort (2014)
Picture
The long-term impact of elevated C-reactive protein levels during pregnancy on brain morphology in late childhood (July 2022)
Conclusion and relevance:Our results suggest sex-specific long-term effects in brain morphology after MIA [Maternal Immune Activation].

Categorical analyses suggest that this association might be driven by acute infections or or other sources of severe inflammation, which is of clinical relevance given that the COVID-19 pandemic is currently affecting millions of pregnant women worldwide. 
Picture
Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank. (2021)

The Crying Need for:   Medical Integrators

10/15/2023

 
Medical Integrators
  • Integrating Information across:
    • Immunology
    • Endocrinology
    • Gastroenterology
    • Psychiatry/Psychology
    • Etc.
 
  • It is beyond frustrating to know that we have so much research BUT we don't have an effective means to integrate it in a "timely and responsible manner."
 
  • We've heard a lot about the need to re-allocate resources in the Society to address COMPLEX PROBLEMS in CRIMINAL JUSTICE.
 
  • We need to think about re-allocating resources, creating/expanding work in MEDICINE to deal with an EXPLOSION OF INFORMATION AND RESEARCH which is exposing that Medical Disciplines are not sufficiently INTEGRATED.

Understanding how SYSTEMIC DEVELOPMENTAL INFLAMMATION and INFLAMMATION ACQUIRED during the lifetime impact HEALTH OUTCOMES is critically important to many chronic diseases, neuro-developmental differences/disorders and psychiatric disorders.

I think there's a vague understanding with regard to INFLAMMATION --- but New & Growing Knowledge regarding the RAMIFICATIONS of SYSTEMIC DEVELOPMENTAL INFLAMMATION ----
  • has the potential to transform our Society and
  • it may be one of the keys to INTEGRATING various medical disciplines.
Picture
The Impact of Systemic Inflammation on Neurodevelopment (2018)
Cytokines and neurodevelopment

In the past several decades, inflammation has been increasingly recognized as an important contributor to central nervous system (CNS) injury in both the developing and adult brain.

The brain is particularly vulnerable in utero as well as during infancy and early childhood, and insults that occur during these critical periods have the potential to cause long-term damage.

Several neurodevelopmental disorders have been linked to early life immune activation and inflammation, including autism spectrum disorders (ASD), schizophrenia, cerebral palsy, epilepsy, cognitive impairment, and depression .
<<Previous
Forward>>

    Translational Medicine Friday

    We're riffing off NPR's Science Friday to create Translational Medicine Friday.

    We'll be collecting Research Article recommendations for Clinicians with regard to Cognitive Disability.

    ​There is much in the RESEARCH JOURNALS and we'll just be SKIMMING THE SURFACE.

    The POINT is to INCREASE FUNDING for TRANSLATIONAL RESEARCH at the Federal Level for the National Institutes of Health, the Centers for Disease Control, the Nation's Research & Teaching Hospitals and possible collaborations with Medicare and Medicaid providers.

    Archives

    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    October 2024
    September 2024
    August 2024
    July 2024
    June 2024
    May 2024
    April 2024
    March 2024
    February 2024
    January 2024
    December 2023
    October 2023
    September 2023
    August 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021

    Categories

    All

    RSS Feed


Orchid:  Email

Crisis Services in Colorado, the US & Around the World

​Copyright 2025  Orchid Mental Health Legal Advocacy of Colorado, Inc.
Web Hosting by iPage
  • Home
    • About Orchid >
      • Why Orchid?
      • ORCHID'S SYSTEMIC FOCUS & "ROOT CAUSE" ANALYSIS APPROACH TO PROBLEM SOLVING WITH A COMMITMENT TO CREATIVITY & INNOVATION
      • Disclaimers, Limitations and An Invitation
      • Orchid Board
      • Orchid Book Club
      • Conjecture, Science & Translational Research & Medicine
      • Orchid Themes & Symbols
      • The Tipping Point
      • Orchid's Website Advertising Policy
      • Statement for Potential Website Contributors
      • Contact
  • Blogs
    • Val's Blog
    • Val's Blog 2
    • ​TRANSLATIONAL/ ​TRANSITIONAL JUSTICE MONDAY
    • NEURO-DIVERSITY Wednesday
    • Olmstead Law & Order Thursday
    • Translational Medicine Friday
    • Translational Love, Relationships & Neuro-Diversity Saturday
  • Orchid's A-Z Index
    • Crisis Services in CO, the US & Around the World
    • Assertive Community Treatment & Flexible ACT Index
    • Housing & Homelessness Index
    • Criminal Justice
    • Innovation Index
    • For More: See the Main Orchid Index Page
  • US Federal
    • THE IMD RULE & ADMIN. ENFORCEMENT OF DISABILITY CIVIL RIGHTS LAWS
    • Medicaid & Supportive Housing & Housing-Related Services
    • CMS' FAILURE TO COVER HOUSING FOR LTC & THE IMD RULE: WHAT THEY HAVE IN COMMON IS DISCRIMINATION
    • National Take
  • Research & Translational Medicine
    • Immunology & Mental Health >
      • Alcoholism & the Immune System & Mental Health
      • Brain Injury, the Immune System & Mental Health
      • Celiac Disease & Sensitivities, the Immune System & Mental Illness
      • Mental Illness & The Immune System
      • Racial Discrimination & the Immune System & Mental Health
      • Trauma & the Immune System & Mental Health
      • ***Physical Health Issues, the Immune System & Mental Health Index
    • University of Chicago: Institute of Translational Medicine
  • Hot Topics
    • What We Want --- SAMHSA Grant Opportunities Due Jan. 22, 2019
    • Anti-Social Personality Disorder >
      • DECONSTRUCTING ANTISOCIAL PERSONALITY DISORDER AND PSYCHOPATHY: A GUIDELINES-BASED APPROACH TO PREJUDICIAL PSYCHIATRIC LABELS [Hofstra Law Review 2013]
      • Personality Disorders -- Unscientific & Vague -- Must Be Reformed
    • Executive Functioning & "Prison Brain" >
      • Job Accommodation Network on Executive Functioning Deficits
    • Medicaid & Medicare Network Adequacy >
      • OIG: STATE STANDARDS FOR ACCESS TO CARE IN MEDICAID MANAGED CARE (Sept. 2014)
      • OIG: ACCESS TO CARE: PROVIDER AVAILABILITY IN MEDICAID MANAGED CARE (Dec. 2014)
      • GAO 15-710: MEDICARE ADVANTAGE: Actions Needed to Enhance CMS Oversight of Provider Network Adequacy (Aug. 2015)
      • CMS: Promoting Access in Medicaid and CHIP Managed Care: A Toolkit for Ensuring Provider Network Adequacy and Service Availability (April 2017)
    • Medicaid Mental Health & Substance Use Disorder Parity >
      • CMS Parity Compliance Toolkit Applying Mental Health and Substance Use Disorder Parity Requirements to Medicaid and Children’s Health Insurance Programs [Jan. 17, 2017]
      • Frequently Asked Questions: Mental Health and Substance Use Disorder Parity Final Rule for Medicaid and CHIP [CMS October 11, 2017]
    • Olmstead Disability Rights >
      • Statement of the Department of Justice on Enforcement of the Integration Mandate of Title II of the Americans with Disabilities Act and Olmstead v. L.C. (2011)
      • Comprehensive Olmstead Planning
      • the Logical Long Term Consequences of our failure to provide Intensive Community MH Treatment
      • Olmstead Nation ---State Pages: How Far to Comply with Olmstead?
  • Take A Walk Around Orchid's Resource Block
  • Colorado Abuse & Neglect Scandals Involving People with Disabilities
  • Mental Health By The Numbers
  • New Science Is Amazing AND It Has HUGE Moral Implications for Our Society: NOW
  • Olmstead & Homelessness
  • Double V
  • " 'Defund the Police" Means 'Invest in the Resources Our Communities Need' " or Don't Cost Shift to the Police
  • VAGUE OLMSTEAD PLANS, EXPENSIVE LITIGATION
  • Updating & Reforming our Understanding & Treatment of "Anti-Social Personality Disorder" Blog
  • Reform of " Anti-Social Personality Disorder" in Criminal Justice
  • CO HB22-1278
  • New Understandings Matter
  • Mental Health, Ethics & Law
  • CO Olmstead Disability Homeless Law & Policy Project
  • Inflammation, the Immune System, Neuro-Developmental Disorders, Psychiatric Disorders, Substance Use Issues & Chronic Disease
  • Microglia and the Brain's Immune System
  • Substance Issues & the Immune System